Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations
- PMID: 8587044
- DOI: 10.1002/jps.2600841106
Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations
Abstract
Interspecies scaling is used to extrapolate pharmacokinetic parameters from animals to humans, through the application of physiologically based models, by empirical allometric procedures, or using concentration-time transformations. The aim of this study was to compare the accuracies of the last two methods for predicting the pharmacokinetic parameters and concentration-time curves in humans. In the first part of this study, interspecies scaling techniques were applied to a hypothetical drug (extracellular distribution and elimination through glomerular filtration), to examine the influence of various laboratory animals (mouse, rat, cynomolgus monkey and dog) on the parameters predicted for man. The same techniques were also applied to interferon-alpha A, using the literature data for various animal species. The kinetic parameters predicted in man were then compared to the values published for man. Our theoretical example showed that, for allometric scaling, each species has a very different influence on the prediction in human. With the approach using concentration-time transformations, however, each animal species potentially makes a similar contribution to the prediction for man. Based on the pharmacokinetic data published for interferon-alpha A in laboratory animals, allometric equations underestimated the observed values of CL and Vdss in man by 2-3-fold, and the prediction of t1/2 was likely to be unreliable, due to a poor correlation. The use of equivalent time, kallynochron, and apolysichron transformations improved the pharmacokinetic predictions for all three parameters in man. In conclusion, concentration-time transformations make more adequate use of the data available in the different species of laboratory animals, to give better predictions of the pharmacokinetic parameters in man.
Similar articles
-
Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor.J Pharm Pharmacol. 1996 Jun;48(6):573-7. doi: 10.1111/j.2042-7158.1996.tb05976.x. J Pharm Pharmacol. 1996. PMID: 8832489
-
Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics.J Pharm Pharm Sci. 2012;15(2):265-80. doi: 10.18433/j34s4n. J Pharm Pharm Sci. 2012. PMID: 22579006
-
Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons.Pharm Res. 2010 May;27(5):920-32. doi: 10.1007/s11095-010-0098-6. Epub 2010 Mar 16. Pharm Res. 2010. PMID: 20232116 Free PMC article.
-
Interspecies scaling: predicting volumes, mean residence time and elimination half-life. Some suggestions.J Pharm Pharmacol. 1998 May;50(5):493-9. doi: 10.1111/j.2042-7158.1998.tb06190.x. J Pharm Pharmacol. 1998. PMID: 9643442 Review.
-
Interspecies allometric analysis of the comparative pharmacokinetics of 44 drugs across veterinary and laboratory animal species.J Vet Pharmacol Ther. 1997 Dec;20(6):453-63. doi: 10.1046/j.1365-2885.1997.00095.x. J Vet Pharmacol Ther. 1997. PMID: 9430769 Review.
Cited by
-
Allometric scaling of xenobiotic clearance: uncertainty versus universality.AAPS PharmSci. 2001;3(4):E29. doi: 10.1208/ps030429. AAPS PharmSci. 2001. PMID: 12049492 Free PMC article.
-
Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations.Clin Pharmacokinet. 1999 Mar;36(3):211-31. doi: 10.2165/00003088-199936030-00003. Clin Pharmacokinet. 1999. PMID: 10223169 Review.
-
Fractal volume of drug distribution: it scales proportionally to body mass.Pharm Res. 2001 Jul;18(7):1056-60. doi: 10.1023/a:1010965001162. Pharm Res. 2001. PMID: 11496945
-
Prediction of drug clearance in humans from laboratory animals based on body surface area.Eur J Drug Metab Pharmacokinet. 2001 Oct-Dec;26(4):249-55. doi: 10.1007/BF03226379. Eur J Drug Metab Pharmacokinet. 2001. PMID: 11808867
-
Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling.J Pharmacokinet Biopharm. 1997 Apr;25(2):149-67. doi: 10.1023/a:1025728028890. J Pharmacokinet Biopharm. 1997. PMID: 9408857
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources